News
HCM
16.80
-0.30%
-0.05
HUTCHMED’s Savolitinib sNDA Under Review in China
TipRanks · 21h ago
On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
The supplemental New Drug Application for savolitinib has been accepted for review by the China National Medical Products Administration. If approved, the label indication for the drug will be expanded to include treatment-naïve patients in China. The drug is being developed for patients with lung cancer.
Benzinga · 23h ago
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Barchart · 1d ago
Weekly Report: what happened at HCM last week (0318-0322)?
Weekly Report · 3d ago
HUTCHMED Advances Sovleplenib Trial in China
TipRanks · 6d ago
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED (China) Limited has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. The company is a subsidiary of HUTCH MEDIA.
Barchart · 03/21 19:00
Hutchmed Is Turning Profitable
Hutchmed (China) Limited is a biopharmaceutical company with a market capitalization of $3 billion. The company's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. HCM delivered a profit of $100.8 million and has a strong cash position of over $880 million. In December, Tudor Invest Holdings upgraded HCM from a Hold to a Buy on expectations of the company turning profitable.
Seeking Alpha · 03/20 12:55
Weekly Report: what happened at HCM last week (0311-0315)?
Weekly Report · 03/18 09:29
Affimed N.V., Hutchmed, Annexon among healthcare movers
Healthcare On the Move Affimed N.V., Hutchmed, Annexon among healthcare movers. S&P 500 Health Care Sector -0.06% to 1702.51. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/14 14:00
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Shares of Hello Group Inc. Fell sharply in today’s pre-market trading after the company reported fourth-quarter financial results. Hello Group shares dipped 19.1% to $6.21 in today's trading. The Dow futures were higher this morning, with the Dow gaining around 100 points.
Benzinga · 03/14 09:52
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Clover Health Investments, Corp. Shares jumped 11.2% to $0.8537 on Wednesday. The company reported better-than-expected fourth-quarter revenue results. Gaxos.ai shares jumped 128.9% after the company acquired rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. And The Beauty Health Company also gained.
Benzinga · 03/13 17:18
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers. S&P 500 Health Care Sector +0.01% to 1710.78. Pharmaceuticals, Biotechnology & Life Science contributes 0.14% to index is -0.12%.
Seeking Alpha · 03/13 14:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. HUTCHMED (China) stock increased by 14.04% in the pre- market session. Kintara Therapeutics (NASdaq:KTRA) and Qilian Intl. Gr (Qilian) were among the losers.
Benzinga · 03/13 13:06
KB Financial, BeiGene, Legend Biotech among premarket gainers' pack
ShiftPixy (PIXY) and Minim (MINM) among premarket gainers' pack. KB Financial, BeiGene, Legend Biotech among the biggest morning stock movers. Biggest gainers in SA on the day were ShiftPixY and ShiftPIXy.
Seeking Alpha · 03/13 12:29
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
SurgePays, Inc. Shares fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results. SurgePays posted GAAP earnings of 19 cents per share, missing market estimates of 41 cents. NuCana plc gained 99.6% to $0.7806 after being granted a U.S. Patent.
Benzinga · 03/13 12:24
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
NuCana stock is rocketing more than 95% alongside heavy pre-market trading on Wednesday morning. Biggest pre- market stock movers include ShiftPixy, Minim and Tenon Medical. Earnings reports, management changes, a merger announcement and more are moving stocks this morning.
Investorplace · 03/13 11:30
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Beauty Health Company shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter revenue results. The Beauty Health shares jumped 17.3% to $4.21. The Nasdaq futures fell by around 20 points on Wednesday.
Benzinga · 03/13 10:16
Weekly Report: what happened at HCM last week (0304-0308)?
Weekly Report · 03/11 09:28
Weekly Report: what happened at HCM last week (0226-0301)?
Weekly Report · 03/04 09:29
HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
TipRanks · 02/28 21:55
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.